Optical coherence tomography-derived lipid core burden index and clinical outcomes: results from the CLIMA registry.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
21 03 2023
Historique:
received: 26 04 2022
accepted: 26 05 2022
pubmed: 20 6 2022
medline: 24 3 2023
entrez: 19 6 2022
Statut: ppublish

Résumé

The aim of this study was to assess the morphological characteristics and prognostic implications of the optical coherence tomography (OCT)-derived lipid core burden index (LCBI). OCT-LCBI was assessed in 1003 patients with 1-year follow-up from the CLIMA multicentre registry using a validated software able to automatically obtain a maximum OCT-LCBI in 4 mm (maxOCT-LCBI4mm). Primary composite clinical endpoint included cardiac death, myocardial infarction, and target-vessel revascularization. A secondary analysis using clinical outcomes of CLIMA study was performed. Patients with a maxOCT-LCBI4mm ≥ 400 showed higher prevalence of fibrous cap thickness (FCT) <75 μm [odds ratio (OR) 1.43, 95% confidence interval (CI) 1.03-1.99; P = 0.034], lipid pool arc >180° (OR 3.93, 95%CI 2.97-5.21; P < 0.001), minimum lumen area <3.5 mm2 (OR 1.5, 95%CI 1.16-1.94; P = 0.002), macrophage infiltration (OR 2.38, 95%CI 1.81-3.13; P < 0.001), and intra-plaque intimal vasculature (OR 1.34, 95%CI 1.05-1.72; P = 0.021). A maxOCT-LCBI4mm ≥400 predicted the primary endpoint [adjusted hazard ratio (HR) 1.86, 95%CI 1.1-3.2; P = 0.019] as well as the CLIMA endpoint (HR 2.56, 95%CI 1.24-5.29; P = 0.011). Patients with high lipid content and thin FCT < 75 µm were at higher risk for adverse events (HR 4.88, 95%CI 2.44-9.72; P < 0.001). A high maxOCT-LCBI4mm was related to poor outcome and vulnerable plaque features. This study represents a step further in the automated assessment of the coronary plaque risk profile.

Identifiants

pubmed: 35718858
pii: 6611496
doi: 10.1093/ehjci/jeac110
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

437-445

Subventions

Organisme : Centro per la Lotta contro l'Infarto - Fondazione Onlus

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflicts of interest: Francesco Burzotta received speaker's fees from Terumo, Abiomed, Abbott, Medtronic. The other Authors declare no conflicts of interest.

Auteurs

Flavio Giuseppe Biccirè (FG)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.
Cardiovascular Sciences Department, Interventional Cardiology Unit, San Giovanni Addolorata Hospital, Via dell'Amba Aradam, 8, Rome 00184, Italy.
Sapienza University of Rome, Rome, Italy.

Simone Budassi (S)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.
Cardiovascular Sciences Department, Interventional Cardiology Unit, San Giovanni Addolorata Hospital, Via dell'Amba Aradam, 8, Rome 00184, Italy.

Yukio Ozaki (Y)

Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.

Alberto Boi (A)

Interventional Cardiology Unit, Ospedale Brotzu, Cagliari, Italy.

Enrico Romagnoli (E)

Departement of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Riccardo Di Pietro (R)

Cardiology Department, Santa Maria Goretti Hospital, Latina, Italy.

Christos V Bourantas (CV)

Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK.
Institute of Cardiovascular Sciences, University College London, London, UK.

Valeria Marco (V)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Giulia Paoletti (G)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.
UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.

Caterina Debelak (C)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Emanuele Sammartini (E)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.

Francesco Versaci (F)

Cardiology Department, Santa Maria Goretti Hospital, Latina, Italy.

Franco Fabbiocchi (F)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Francesco Burzotta (F)

Departement of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Daniele Pastori (D)

Sapienza University of Rome, Rome, Italy.

Filippo Crea (F)

Departement of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Eloisa Arbustini (E)

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.

Fernando Alfonso (F)

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.

Francesco Prati (F)

Centro per la Lotta Contro L'Infarto - CLI Foundation, Rome, Italy.
Cardiovascular Sciences Department, Interventional Cardiology Unit, San Giovanni Addolorata Hospital, Via dell'Amba Aradam, 8, Rome 00184, Italy.
UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH